These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29137637)

  • 21. Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013.
    Stekler JD; McKernan J; Milne R; Tapia KA; Mykhalchenko K; Holte S; Maenza J; Stevens CE; Buskin SE; Mullins JI; Frenkel LM; Collier AC
    Antivir Ther; 2015; 20(1):77-80. PubMed ID: 24831260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.
    Nguyen HL; Ruxrungtham K; Delaugerre C
    Intervirology; 2012; 55(4):287-95. PubMed ID: 22456540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-naïve individuals.
    Margot NA; Ram RR; White KL; Abram ME; Callebaut C
    J Med Virol; 2019 Dec; 91(12):2188-2194. PubMed ID: 31389026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV type 1 integrase polymorphisms in treatment-naive and treatment-experienced HIV type 1-infected patients in Thailand where HIV type 1 subtype A/E predominates.
    Phuphuakrat A; Pasomsub E; Kiertiburanakul S; Chantratita W; Sungkanuparph S
    AIDS Res Hum Retroviruses; 2012 Aug; 28(8):937-43. PubMed ID: 21970343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of primary mutations associated with integrase inhibitors among HIV-1 subtypes B, C, and F circulating in Brazil.
    Passaes CB; Guimarães ML; Fernandez SL; Lorete Rdos S; Teixeira SL; Fernandez JC; Morgado MG
    J Acquir Immune Defic Syndr; 2009 May; 51(1):7-12. PubMed ID: 19262402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of a new 2-amino acid insertion in the integrase coding region of HIV-1 subtype G isolates.
    Pereira-Vaz J; Crespo P; Mocho L; Martinho P; Fidalgo T; Correia L; Rodrigues F; Duque V
    J Med Virol; 2021 Nov; 93(11):6388-6392. PubMed ID: 34260070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.
    Tzou PL; Rhee SY; Descamps D; Clutter DS; Hare B; Mor O; Grude M; Parkin N; Jordan MR; Bertagnolio S; Schapiro JM; Harrigan PR; Geretti AM; Marcelin AG; Shafer RW;
    J Antimicrob Chemother; 2020 Jan; 75(1):170-182. PubMed ID: 31617907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.
    Modica S; Rossetti B; Lombardi F; Lagi F; Maffeo M; D'Autilia R; Pecorari M; Vicenti I; Bruzzone B; Magnani G; Paolucci S; Francisci D; Penco G; Sacchini D; Zazzi M; De Luca A; Di Biagio A
    HIV Med; 2019 Feb; 20(2):137-146. PubMed ID: 30461149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low level of HIV-1C integrase strand transfer inhibitor resistance mutations among recently diagnosed ART-naive Ethiopians.
    Kiros M; Tefera DA; Andualem H; Geteneh A; Tesfaye A; Woldemichael TS; Kidane E; Alemayehu DH; Maier M; Mihret A; Abegaz WE; Mulu A
    Sci Rep; 2023 Apr; 13(1):6546. PubMed ID: 37085698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance-Associated Mutations and Polymorphisms among Integrase Inhibitor-Naïve HIV-1 Patients in Kuwait.
    Chehadeh W; Albaksami O; John SE; Al-Nakib W
    Intervirology; 2017; 60(4):131-137. PubMed ID: 29212076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV Type 1 Integrase Natural Polymorphisms in Viral Variants Circulating in FSU Countries.
    Lapovok I; Laga V; Kazennova E; Bobkova M
    Curr HIV Res; 2017 Nov; 15(5):318-326. PubMed ID: 28814231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypes.
    Sierra S; Lübke N; Walter H; Schülter E; Reuter S; Fätkenheuer G; Bickel M; da Silva H; Kaiser R; Esser S;
    Med Microbiol Immunol; 2011 Nov; 200(4):225-32. PubMed ID: 21475993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
    Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
    J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic variation of the HIV-1 integrase region in newly diagnosed anti-retroviral drug-naïve patients with HIV/AIDS in Korea.
    Kim JY; Kim EJ; Choi JY; Kwon OK; Kim GJ; Choi SY; Kim SS
    Clin Microbiol Infect; 2011 Aug; 17(8):1155-9. PubMed ID: 20946407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness.
    Wares M; Mesplède T; Quashie PK; Osman N; Han Y; Wainberg MA
    Retrovirology; 2014 Jan; 11():7. PubMed ID: 24433497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of HIV-1 integrase genotypes and polymorphisms among integrase inhibitors-based antiretroviral treatment naïve patients in South Sudan.
    Giovanetti M; Farcomeni S; Sernicola L; Virtuoso S; Fontanelli Sulekova L; Maggiorella MT; Buttò S; Taliani G; Ciccozzi M; Borsetti A
    J Med Virol; 2022 Jul; 94(7):3320-3327. PubMed ID: 35277871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Presence of V72I, G123S and R127K Integrase Inhibitor polymorphisms could reduce ART effectiveness: a retrospective longitudinal study.
    Celotti A; Gargiulo F; Quiros-Roldan E; Properzi M; De Francesco MA; Coletto D; Caccuri F; Izzo I; Caruso A; Castelli F; Focà E
    HIV Res Clin Pract; 2020 Feb; 21(1):24-33. PubMed ID: 32141388
    [No Abstract]   [Full Text] [Related]  

  • 38. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.
    Brenner BG; Lowe M; Moisi D; Hardy I; Gagnon S; Charest H; Baril JG; Wainberg MA; Roger M
    J Med Virol; 2011 May; 83(5):751-9. PubMed ID: 21360548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV-1 integrase polymorphisms are associated with prior antiretroviral drug exposure.
    van Hal SJ; Herring B; Deris Z; Wang B; Saksena NK; Dwyer DE
    Retrovirology; 2009 Feb; 6():12. PubMed ID: 19203393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-1 diversity and pre-treatment drug resistance in the era of integrase inhibitor among newly diagnosed ART-naïve adult patients in Luanda, Angola.
    Sebastião CS; Abecasis AB; Jandondo D; Sebastião JMK; Vigário J; Comandante F; Pingarilho M; Pocongo B; Cassinela E; Gonçalves F; Gomes P; Giovanetti M; Francisco NM; Sacomboio E; Brito M; Neto de Vasconcelos J; Morais J; Pimentel V
    Sci Rep; 2024 Jul; 14(1):15893. PubMed ID: 38987263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.